Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-311597

ABSTRACT

Aims: : To identify the risk factors of mortality for coronavirus disease 19 (COVID-19) patients admitted to intensive care units (ICU), we conducted a retrospective analysis. Methods: : The demographic characteristics, laboratory findings and chest X-ray data of COVID-19 patients admitted to ICU of Huoshenshan Hospital from February 10 to April 10, 2020 were retrospectively analyzed. Student's t test and chi-square test were used to compare continuous variables, categorical variables respectively. Logistic regression model was used to seek risk factors of mortality. Results: : A total of 57 patients (38 males and 19 females) were included in this retrospective study, including 20 patients in deceased group and 37 patients in surviving group. Leukocyte count, neutrophil count, lymphocyte count, eosinophil count, neutrophil-to-lymphocyte ratio (NLR), urea nitrogen, lactate dehydrogenase (LDH), interleukin-6 (IL-6), C-reactive protein (CRP), arterial partial pressure of oxygen/oxygen concentration (PaO2/FiO2) and imaging findings were statistically different between the two groups. The multivariate logistic regression analysis identified IL-6 and PaO2/FiO2 as independent risk factors of mortality. The area of under curves (AUC) of IL-6 and PaO2/FiO2 were 0.9 (95%CI:0.823-0.977, p<0.0001) and 0.865 (95%CI:0.774-0.956, p<0.0001) respectively. The cut-off value of IL-6 was 25.69 pg/mL, the sensitivity was 95% and the specificity was 75.7%, while the cut-off value of PaO2/FiO2 was 167.79 mmHg, the sensitivity was 75.7% and the specificity was 85%. Conclusion: Clinicians should pay enough attention to IL-6 and PaO2/FiO2, especially when IL-6>25.69 pg/ml and PaO2/FiO2<167.79 mmHg, and take active intervention measures as early as possible.

2.
Sci Rep ; 11(1): 7334, 2021 04 01.
Article in English | MEDLINE | ID: covidwho-1500696

ABSTRACT

To identify the risk factors of mortality for the coronavirus disease 19 (COVID-19) patients admitted to intensive care units (ICUs) through a retrospective analysis. The demographic, clinical, laboratory, and chest imaging data of patients admitted to the ICU of Huoshenshan Hospital from February 10 to April 10, 2020 were retrospectively analyzed. Student's t-test and Chi-square test were used to compare the continuous and categorical variables, respectively. The logistic regression model was employed to ascertain the risk factors of mortality. This retrospective study involved 123 patients, including 64 dead and 59 survivors. Among them, 57 people were tested for interleukin-6 (IL-6) (20 died and 37 survived). In all included patients, the oxygenation index (PaO2/FiO2) was identified as an independent risk factor (odd ratio [OR] = 0.96, 95% confidence interval [CI]: 0.928-0.994, p = 0.021). The area under the curve (AUC) was 0.895 (95% CI: 0.826-0.943, p < 0.0001). Among the patients tested for IL-6, the PaO2/FiO2 (OR = 0.955, 95%CI: 0.915-0.996, p = 0.032) and IL-6 (OR = 1.013, 95%CI: 1.001-1.025, p = 0.028) were identified as independent risk factors. The AUC was 0.9 (95% CI: 0.791-0.964, p < 0.0001) for IL-6 and 0.865 (95% CI: 0.748-0.941, p < 0.0001) for PaO2/FiO2. PaO2/FiO2 and IL-6 could potentially serve as independent risk factors for predicting death in COVID-19 patients requiring intensive care.


Subject(s)
COVID-19/mortality , Interleukin-6/analysis , Aged , Area Under Curve , COVID-19/pathology , COVID-19/virology , Comorbidity , Female , Humans , Intensive Care Units , Logistic Models , Male , Middle Aged , Oxygen Consumption , ROC Curve , Retrospective Studies , Risk Factors , SARS-CoV-2/isolation & purification
3.
Ann Palliat Med ; 10(2): 1928-1949, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1068178

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) is an emerging pandemic of global public health concern. We aimed to summarize the characteristics of COVID-19 patients in the early stage of the pandemic and explore the risk factors of disease progression. METHODS: We conducted a systematic review with meta-analysis, searching three databases for studies published between January 1, 2020, and March 18, 2020. We used random-effects models to calculate the 95% confidence intervals of pooled estimated prevalence and the odds ratio between the severe and nonsevere cases. RESULTS: Ninety studies involving 16,526 COVID-19 patients were included. Hypertension (19.1%) and diabetes (9.5%) were the most common comorbidities. The most prevalent clinical symptoms were fever (78.4%), cough (58.5%), and fatigue (26.4%). Increased serum ferritin (74.2%), high C-reactive protein (73.3%), and high erythrocyte sedimentation rate (ESR) (72.2%) were the most frequently reported laboratory abnormalities. Most patients had bilateral lung involvement (82.2%) and showed peripheral (66.9%) and subpleural (62.1%) distribution, with multifocal involvement (73.1%). And the most common CT features were vascular enlargement (64.3%), ground-glass opacity (GGO) (60.7%), and thickened interlobular septa (55.1%). Respiratory failure was the most common complication (30.7%) and the overall case-fatality rate (CFR) was 4.2%. Moreover, male, history of smoking, and comorbidities might influence the prognosis. Most clinical symptoms such as fever, high fever, cough, sputum production, fatigue, shortness of breath, dyspnoea, and abdominal pain were linked to the severity of disease. Some specific laboratory indicators implied the deterioration of disease, such as leucocytosis, lymphopenia, platelet, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, creatinine, creatine kinase (CK), lactic dehydrogenase (LDH), C-reactive protein, procalcitonin (PCT), and D-dimer. Besides, the risk of bilateral pneumonia, consolidation, pleural effusion, and enlarged mediastinal nodes was higher in severe cases. CONCLUSIONS: Most COVID-19 patients have fever and cough with lymphopenia and increased inflammatory indices, and the main CT feature is GGO involved bilateral lung. Patients with comorbidities and worse clinical symptoms, laboratory characteristics, and CT findings tend to have poor disease progression.


Subject(s)
COVID-19/diagnosis , Biomarkers/blood , COVID-19/blood , COVID-19/pathology , Comorbidity , Cough , Fever , Humans , Inflammation , Lung/diagnostic imaging , Lung/pathology , Lymphopenia , Retrospective Studies , Risk Factors , Tomography, X-Ray Computed
5.
Transpl Infect Dis ; 22(5): e13329, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-272577

ABSTRACT

Coronavirus disease 2019 (COVID-19) has been a pandemic worldwide. The data about COVID-19 in renal transplant recipient are deficiency. Herein, we report two COVID-19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low-dose methylprednisolone-based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID-19 in renal transplant recipients.


Subject(s)
COVID-19/diagnosis , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Methylprednisolone/administration & dosage , SARS-CoV-2/immunology , Aged , COVID-19/drug therapy , COVID-19/immunology , COVID-19/virology , COVID-19 Testing , Dose-Response Relationship, Drug , Female , Graft Rejection/immunology , Graft Rejection/prevention & control , Humans , Immunocompromised Host , Lung/diagnostic imaging , Male , Middle Aged , SARS-CoV-2/isolation & purification , Tomography, X-Ray Computed , Transplant Recipients , Treatment Outcome
7.
J Med Virol ; 92(10): 1890-1901, 2020 10.
Article in English | MEDLINE | ID: covidwho-60287

ABSTRACT

The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergencies. A handful pieces of literature have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. To evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. Six laboratory-confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground-glass opacities and consolidation in patients #1, #2, #3, #4, and #6. In patients #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of the virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patients #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-the-art therapy during COVID-19 pandemic crisis.


Subject(s)
COVID-19/therapy , Adult , Aged , Antibodies, Viral/blood , China , Female , Humans , Immunization, Passive , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged
9.
Brain Behav Immun ; 88: 945-946, 2020 08.
Article in English | MEDLINE | ID: covidwho-45865
SELECTION OF CITATIONS
SEARCH DETAIL